<?xml version="1.0" ?>
<tei>
	<teiHeader>
		<fileDesc xml:id="55001994"/>
	</teiHeader>
	<text xml:lang="en">
		<front>
<lb/>
	<docTitle>
	<titlePart>End-organ damage: does it really matter how we<lb/> prevent it?<lb/></titlePart>
	</docTitle>

	<byline>
	<docAuthor>B. Dahlöf<lb/></docAuthor>
	</byline>

	<byline>
	<affiliation>Sahlgrenska University Hospital/Östra,</affiliation>
	</byline>

	<address>Göteborg, Sweden<lb/></address>

<reference>European Heart Journal Supplements (2003) 5 (Supplement F), F33—F39</reference>
<div type="abstract"><lb/> Studying left ventricular hypertrophy (LVH) allows the most comprehensive<lb/> evaluation of end-organ damage prevention. Clinical trials show that renin—<lb/> angiotensin—aldosterone system blockade confers protective effects that are not<lb/> simply due to antihypertensive activity. Angiotensin II receptor blockers (ARBs),<lb/> which offer specific and complete inhibition of the action of angiotensin II at the<lb/> level of the angiotensin II type 1 (AT 1 ) receptor, have proved more effective than<lb/> other antihypertensive classes in reversing LVH and interstitial collagen<lb/> accumulation. The Losartan Intervention For Endpoint reduction in hypertension<lb/> (LIFE) study, for example, showed that a losartan-based therapy resulted in better<lb/> LVH regression than an atenolol-based one, despite similar blood pressure control<lb/> with both treatment regimens. Other clinical studies demonstrated that ARB-<lb/>induced reduction in fibrosis is linked to functional improvement. It is still not<lb/> known whether more effective angiotensin II blockade will provide more complete<lb/> LVH reversal, improve cardiac function, prevent damage to other target organs and<lb/> enhance prognosis. To find the answer, The ONgoing Telmisartan Alone and in<lb/> combination with Ramipril Global Endpoint Trial (ONTARGET) Trial Programme will<lb/> compare 24-h active AT 1 blockade with telmisartan versus established angiotensin-<lb/>converting enzyme (ACE) inhibition using ramipril versus AT 1 blockade plus ACE<lb/> inhibition.<lb/></div>

	<note type="copyright">© 2003 The European Society of Cardiology. Published by Elsevier Science Ltd. All<lb/> rights reserved<lb/> </note>
	
	<keyword>KEYWORDS<lb/> Endothelial dysfunc-<lb/>tion;<lb/> Left ventricular hyper-<lb/>trophy;<lb/> Renin—angiotensin— aldosterone system;<lb/> Target organ damage;<lb/> Treatment<lb/></keyword>

		</front>
	</text>
</tei>
